Dallah Healthcare
دله الصحيةTechnical Analysis & Signals
Dallah Healthcare stock shows an upward trend with positive signals in technical analysis.
Technical Analysis
Dallah Healthcare stock (4004.SR) shows a clear upward trend, currently trading at SAR 124.6. The Relative Strength Index (RSI) at 66.5 indicates that the stock may be in the buying zone, reflecting positive momentum.
Support & Resistance Levels
The main support level for the stock is SAR 120.0, while the resistance level is at SAR 128.52. The stock may experience fluctuations around these levels in the upcoming period.
Volume Analysis
Volume analysis indicates notable trading activity in the stock, enhancing the likelihood of the upward trend continuing. There may be an increase in demand for the stock, which could support prices in the future.
Fundamental Factors
Fundamental factors such as the price-to-earnings (P/E) ratio at 23.2 and a dividend yield of 1.65% indicate a moderate valuation for the stock. These factors are expected to influence investor decisions in the Saudi market.
Risk Factors
Potential risks that the stock may face include general market volatility and unexpected economic impacts. These factors could affect the stock's performance in the future.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Investors are advised to conduct their own research before making any investment decisions.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Dallah Healthcare
4004Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Above Upper BandTrend Strength (ADX)
Moderate TrendFinancial Summary
Valuation
- Market Cap
- 12.61B
- P/E Ratio
- 23.20
- P/B Ratio
- 3.10
- EPS (Earnings/Share)
- 5.38
Profitability
- Revenue
- 4.07B
- Net Income
- 538.27M
- Return on Equity (ROE)
- +10.00%
- Shares Outstanding
- 101.20M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 3.93B
- Debt/Equity
- 0.95
- Free Float %
- +43.1%
Dividends & Margins
- Dividend Yield
- +1.65%
- Dividend/Share
- 2.00
- Book Value
- 40.19
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
4 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2024 | 3.21B +8.9% | 471.20M +30.8% | 6.61B +6.0% | 2.02B +2.5% | 4.66 +30.9% |
| 2023 | 2.94B +18.3% | 360.12M +31.2% | 6.24B +26.9% | 1.97B -0.2% | 3.56 +31.4% |
| 2022 | 2.49B +18.2% | 274.46M +6.1% | 4.92B +5.9% | 1.98B +4.7% | 2.71 +5.9% |
| 2021 | 2.11B | 258.60M | 4.65B | 1.89B | 2.56 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Tadawul-listed firms likely to announce dividends in March
Completion of Kingdom Hospital acquisition boosts Dallah Healthcare's strong presence in Riyadh
Dallah Healthcare completes Care Shield acquisition
Dallah signs deal with Maharah subsidiary to buy stake in Care Shield for SAR 434.3M
AlJazira Capital sets potential changes in MSCI February index review
Ubhar Capital issues Q4 2025 earnings forecasts
Saudi healthcare sector in Q4 2025: Key events likely to impact performance
Key events to drive Saudi-listed firms' performance in Q4 2025
News source: Argaam (argaam.com)
Sector Comparison
| Symbol | Name | Price | Change% |
|---|---|---|---|
| 4013 | Dr. Sulaiman Al Habib | 249.10 SAR | |
| 4002 | Mouwasat | 71.10 SAR | |
| 4004 | Dallah Healthcare | 124.60 SAR | |
| 4017 | Fakeeh Care | 32.40 SAR | |
| 4018 | Almoosa | 137.10 SAR | |
| 4005 | CARE | 130.70 SAR | |
| 4019 | SMC Healthcare | 17.70 SAR | |
| 4007 | Alhammadi | 25.72 SAR |
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-03-26
Risk Assessment
Risk Factors
Average True Range 3.2% of stock price
Trading volume near or above average
P/E ratio 23.2
Debt-to-equity ratio 0.95
ADX indicator at 30
Stable fundamentals, low volatility, and good financial solvency
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Dallah Healthcare stock price today?
Dallah Healthcare (4004) stock price today is 124.60 SAR, gaining by +2.98% compared to the previous session close. The 52-week price range is between 89.62 SAR and 156.09 SAR.
2 What is Dallah Healthcare stock valuation?
The automated analysis signal for Dallah Healthcare is "Buy" with 75% confidence. The P/E ratio is 23.2. The P/B ratio is 3.10.
3 Is Dallah Healthcare Shariah-compliant?
Yes, Dallah Healthcare (4004) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Dallah Healthcare dividend distributions?
Dallah Healthcare has a dividend yield of 1.65%, with an estimated annual dividend of 2.00 SAR per share.
5 What is Dallah Healthcare weekly performance?
Dallah Healthcare performance over different time periods: weekly change +11.53%, monthly +11.82%, and year-to-date -0.05%. The stock is currently trading with a volume of 236,606 shares.
6 What is the target level for Dallah Healthcare?
According to automated analysis for Dallah Healthcare: Short-term target (1-2 weeks): 130.00 SAR. Medium-term target (1-3 months): 140.00 SAR. Support level: 120.00 SAR. Resistance level: 128.52 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.